Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 72% of modeled bridge. Strengths: Occupancy Rate, Commercial Payer %. Risks: Revenue per Bed. Risk-adjusted uplift: $0.2M (vs $0.3M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $118K | $8K | $126K | $0 | 12mo |
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $122K | $122K | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $19K | $56K | $74K | $234K | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $10K | $10K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 57.9% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Denial Rate Reduction | $0 | $31K | $63K | $94K | $126K | $126K | $126K | $126K |
| Cost to Collect | $0 | $31K | $61K | $92K | $122K | $122K | $122K | $122K |
| A/R Days Reduction | $0 | $25K | $50K | $74K | $74K | $74K | $74K | $74K |
| Clean Claim Rate | $0 | $5K | $10K | $10K | $10K | $10K | $10K | $10K |
| Cumulative | $0 | $92K | $183K | $270K | $332K | $332K | $332K | $332K |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $332K is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 155% / 107.1x | 160% / 119.4x | 165% / 131.6x | 168% / 137.8x | 170% / 143.9x |
| 9.0x | 149% / 94.8x | 154% / 105.8x | 159% / 116.7x | 161% / 122.1x | 164% / 127.5x |
| 10.0x | 143% / 85.0x | 149% / 94.8x | 153% / 104.7x | 156% / 109.6x | 158% / 114.5x |
| 11.0x | 138% / 77.0x | 144% / 85.9x | 149% / 94.8x | 151% / 99.3x | 153% / 103.8x |
| 12.0x | 134% / 70.3x | 139% / 78.5x | 144% / 86.7x | 146% / 90.8x | 149% / 94.8x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 91% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 0.6x, adding 7.9 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $24K | — | $24K | 0.4% |
| Year 1 | $25K | +$221K | $246K | 4.0% |
| Year 2 | $25K | +$332K | $357K | 5.8% |
| Year 3 | $26K | +$332K | $358K | 5.9% |
| Year 4 | $27K | +$332K | $359K | 5.9% |
| Year 5 | $28K | +$332K | $360K | 5.9% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Denial Rate Reductio | $63K | $94K | $126K | $151K |
| Cost to Collect | $61K | $92K | $122K | $147K |
| A/R Days Reduction | $37K | $56K | $74K | $89K |
| Clean Claim Rate | $5K | $7K | $10K | $12K |
| Total | $166K | $249K | $332K | $398K |
Peer Context — Where This Hospital Sits
Key metrics vs 25 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 0.4% | -5.7% | 11.8% | 21.2% | P35 |
| Net-to-Gross | 43.8% | 29.2% | 48.6% | 57.9% | P43 |
| Occupancy | 68.7% | 20.0% | 48.4% | 75.6% | P68 |
| Rev/Bed | $679K | $440K | $694K | $1.6M | P48 |
| Exp/Bed | $676K | $406K | $498K | $1.1M | P56 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.